MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 237-239

  Bo, Michele Dal ^a   Secchiero, Paola ^b   Degan, Massimo ^a   Marconi, Daniela ^a   Bomben, Riccardo ^a   Pozzato, Gabriele ^c   Gaidano, Gianluca ^d   Del Poeta, Giovanni ^e   Forconi, Francesco ^f   Zauli, Giorgio ^b   Gattei, Valter ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

CLL; MDM4; Nutlin 3

Indexed keywords

NUTLIN 3; PROTEIN MDMX; PROTEIN P53;

APOPTOSIS; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; LETTER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954325942     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08185.x     Document Type: Letter

References (10)

1. Coll-Mulet, L., Iglesias-Serret, D., Santidrian, A.F., Cosialls, A.M., de, F.M., Castano, E., Campas, C., Barragan, M., de Sevilla, A.F., Domingo, A., Vassilev, L.T., Pons, G. Gil, J. (2006) MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood, 107, 4109 4114.
2. Gilkes, D.M., Pan, Y., Coppola, D., Yeatman, T., Reuther, G.W. Chen, J. (2008) Regulation of MDMX expression by mitogenic signaling. Molecular and Cellular Biology, 28, 1999 2010.
3. Hu, B., Gilkes, D.M., Farooqi, B., Sebti, S.M. Chen, J. (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. Journal of Biological Chemistry, 281, 33030 33035.
4. Moreno, C. Montserrat, E. (2008) New prognostic markers in chronic lymphocytic leukemia. Blood Reviews, 22, 211 219.
5. Patton, J.T., Mayo, L.D., Singhi, A.D., Gudkov, A.V., Stark, G.R. Jackson, M.W. (2006) Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Research, 66, 3169 3176.
6. Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M.G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A. Zauli, G. (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 107, 4122 4129.
7. Shvarts, A., Steegenga, W.T., Riteco, N., van, L.T., Dekker, P., Bazuine, M., van Ham, R.C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A.J. Jochemsen, A.G. (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO Journal, 15, 5349 5357.
8. Terzian, T., Wang, Y., Van Pelt, C.S., Box, N.F., Travis, E.L. Lozano, G. (2007) Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Molecular and Cellular Biology, 27, 5479 5485.
9. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. Liu, E.A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844 848.
10. Zauli, G., di Iasio, M.G., Secchiero, P., Dal, B.M., Marconi, D., Bomben, R., Del, P.G. Gattei, V. (2009) Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Current Cancer Drug Targets, 9, 510 518.